Lab Information
Waqqas Afif (MD/MSc)
InvestigatorClinical Research Unit
Department of Medicine (McGill)
Research Profile
Keywords
Inflammatory bowel disease • Crohn's disease • ulcerative colitis • biologic medications • therapeutic drug monitoringResearch Interests
My research focuses on the safety and efficiency of biologic medications in the treatment of IBD. I am interested in the use of therapeutic drug monitoring to optimize the treatment of IBD patients on biologic medications.Team Members
| Name | Position |
|---|
Latest Publications
- Rosenfeld, G., Narula, N., Leung, Y., Afif, W., Williams, A.-J., Huang, V., Singh, H., McCurdy, J. D., Jairath, V., Lam, M., Loomes, D. E., Zezos, P., Stewart, M., Ma, C., Ropeleski, M., Ancheta-Schmit, M., Tavakoli, P., Bone, J. N., Lewis, J. D., Colombel, J.-F. & Bressler, B. (2026). Proactive Fecal Calprotectin Home Monitoring in Ulcerative Colitis: Results of a Prospective Randomized Control Trial. Gastroenterology.
- De Marco, D., McHugh, K., Plamondon, S., Rioux, L.-C., Steinhart, A. H., Horvat, M. & Afif, W. (2026). An observational cohort study evaluating adalimumab concentrations for predicting non-recapture of biochemical response after dose escalation in patients with Crohn's disease experiencing secondary loss of response. Journal of the Canadian Association of Gastroenterology, vol. 9, p. 153-161.
- Dubé, L.-R., Sorin, M., Allez, M., Afif, W., Bitton, A., Lakatos, P. L., Wild, G., Magro, F., Patel, A., Guardiola, J. & Bessissow, T. (2026). The Association of Faecal Calprotectin Measurements With Endo-Histological Remission in Ulcerative Colitis: A Pooled Analysis. Alimentary pharmacology & therapeutics.
- Lichtenstein, G. R., Allegretti, J. R., Rubin, D. T., Magro, F., Bressler, B., Panés, J., Afif, W., Samaan, M. A., Ye, B. D., Yarandi, S., Germinaro, M., Shipitofsky, N., Miao, Y., Zhang, H., Dignass, A., Sands, B. E., Hisamatsu, T. & Peyrin-Biroulet, L. (2026). Efficacy and Safety of Guselkumab for Ulcerative Colitis Through Week 92 of the QUASAR Long-Term Extension Study. The American journal of gastroenterology.
- Shahrokh, D. K., Vender, R. B., Lynde, C. W., Rao, J., Afif, W., Steinhart, A. H., Narula, N., Sutton, E., Thorne, C. & Bessette, L. (2026). Evaluation of Injection Site Pain and Adherence in Patients Transitioning from a High to Low Volume Adalimumab Formulation (AVT02, Simlandi®) Across Multiple Indications (EASE PAIN). Rheumatology and therapy, vol. 13, p. 745-765.
- Niyigena, E., Hoffert, Y., Afif, W., Pedicelli, A., Roblin, X., Hanžel, J., Papamichael, K., Kobayashi, T., Elens, L., Wang, Z., Ferrante, M., Verstockt, B., Vermeire, S., Vande Casteele, N., Battat, R. & Dreesen, E. (2026). Personalized infliximab rescue therapy to maximize colectomy-free survival in patients with acute severe ulcerative colitis. Journal of Crohn's & colitis, vol. 20.
- Moura, C. S., Etingin, A., Lukusa, L., Singh, H., Narula, N., Targownik, L. E., Leung, Y., Zezos, P., Polewiczowska-Nowak, B., Afif, W. & Bernatsky, S. (2026). Comparable remission and health care use in real-world inflammatory bowel disease patients initiating originator biologics vs biosimilars. World journal of gastroenterology, vol. 32, p. 114580.
- Kritzinger, J., Candel, I., Kotrri, G., Nadeem, H., Afif, W., Bitton, A., Wild, G., Bessissow, T. & Lakatos, P. L. (2025). Clinical outcomes and drug sustainability after non-medical switch from ustekinumab originator to biosimilars in inflammatory bowel disease. World journal of gastroenterology, vol. 31, p. 114355.
- Avinashi, V., Gupta, M., Payne, B. A., Amhaz, H., Temirova, A. T., Afif, W., Ashok, D., Barkey, J., Burnett, D., Bush, J. W., Cameron, S., Carr, S., El Demellawy, D., Erdle, S., Huynh, H. Q., Griffin, J., Grover, S. C., Grzywacz, K., Jeimy, S., Ko, H. H., Lacuesta, G., Marcon, M., Mayrand, S., Petropolis, H., Rodrigues, D., Sherlock, M., Song, C., Tardio, N., Vander Leek, T. K., Vurzinger, M., Williams, B., Xenodemetroupolous, T., Ma, C. & Chan, E. S. (2025). Recommendations for the diagnosis and management of eosinophilic esophagitis in adults and children in Canada: a Delphi consensus project. Journal of the Canadian Association of Gastroenterology, vol. 8, p. 207-227.
- Oketola, B., Bernatsky, S., Lukusa, L., Moura, C. S., Neville, A., Leung, Y., Narula, N., Afif, W., Birck, M. G., Zezos, P., Singh, H. & Canadian IBD Research Consortium (2026). Drug Discontinuation and Persistent Symptoms Among Initiators of Bio-Originator and Biosimilar anti-Tumor Necrosis Factor Drugs in Inflammatory Bowel Disease: Real-World Contemporary Data From the CAnadian Network for Advanced Interdisciplinary Methods/CIRC Registry. Gastro hep advances, vol. 5, p. 100821.
See also
